Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kosan drug fails prostate cancer trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Kosan's epothilone compound KOS-862 (epothilone D) did not meet the primary endpoint of response in a Phase II trial in hormone refractory prostate cancer, the firm says Oct. 18. The company is discontinuing the trial and focusing on an ongoing Phase II study of KOS-862 as monotherapy in metastatic breast cancer. KOS-862 inhibits cancer cells by the same mechanism as taxanes, Kosan explains. A follow-on compound to KOS-862, KOS-1584, is in Phase I. Kosan is developing its epothilones under a 2002 agreement with Roche...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel